

IS 21 From Evolution to Revolution: New Mechanisms of Action in Ulcerative Colitis

NOV

5TH

2025 | 7:00pm CET

Sponsored by

ABIVAX

Recent advances in ulcerative colitis drug development have opened new therapeutic perspectives. This webinar brings together leading experts to discuss the latest phase 3 results with Obefazimod and explore future directions, including subgroup outcomes and combination therapy potential.

7:00 | 7:05pm

Welcome & Introduction 5'

Bruce E. Sands (United States of America)

7:05 | 7:15pm

The Evolution of UC Drug Development 10'

Raja Atreya (Germany)

7:15 | 7:30pm

A New Chapter: Phase 3 Induction Results with Obefazimod 15'

Bruce E. Sands (United States of America)

7:30 | 7:50pm

Exploring Subgroup Outcomes and Potential for Combination Therapy 20'

Silvio Danese (Italy)

7:50 | 8:00pm

Q&A 10'

Raja Atreya (Germany)

Bruce E. Sands (United States of America)

Silvio Danese (Italy)

CLICK HERE TO REGISTER



Silvio DANESE

DIRECTOR, GASTROENTEROLOGY AND ENDOSCOPY
IRCCS SAN RAFFAELE HOSPITAL, MILAN, ITALY
PROFESSOR OF GASTROENTEROLOGY
UNIVERSITY VITA-SALUTE SAN RAFFAELE, MILAN, ITALY



Bruce E. SANDS

PROFESSOR OF MEDICINE AND CHIEF,
DR. HENRY D. JANOWITZ DIVISION OF
GASTROENTEROLOGY, ICAHN SCHOOL OF
MEDICINE AT MOUNT SINAI IN NEW YORK



Raja ATREYA

HEAD OF THE INFLAMMATORY BOWEL DISEASE (IBD)
UNIT AND CLINICAL STUDY CENTRE OF THE UNIVERSITY
HOSPITAL ERLANGEN, FRIEDRICH-ALEXANDER UNIVERSITY,
ERLANGEN-NÜRNBERG, GERMANY

ORGANIZATION OFFICE



Materia Prima
materia1a.it
segreteria@materia1a.it